The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria addressed cardiolipin peroxidation inhibitors. Mitotech is developing several drug formulations of SkQ1 covering a variety of therapeutic areas and methods of administration. The most advanced SkQ1-based drug product in Mitotech’s pipeline is Visomitin® which reached Phase III stage in the U.S. for Dry Eye Disease. Multifactorial nature of Dry Eye made this indication a perfect target for SkQ1 as molecule’s mechanism of action addresses its most important aspects: tear quality, cornea/conjunctiva healing rate and inflammation.
Other indications in Mitotech’s pipeline include other ophthalmic (LHON, dry AMD, uveitis and more), neurodegenerative, cardiovascular and metabolic disorders and are at various earlier stages of clinical development.